Health Trials

About this trial

Urokinase plasminogen activator receptor (uPAR), the cell-surface receptor for its ligand uPA, plays a critical role in regulating cell migration and invasion-key drivers of cancer progression. This study aims to evaluate a novel uPAR-targeting radiopharmaceutical pair: the diagnostic agent \[⁶⁸Ga\]Ga-HT547 and the therapeutic agent \[¹⁷⁷Lu\]Lu-HT547. In patients with breast cancer, head and neck cancer, pancreatic cancer, or glioma, we will assess the diagnostic performance and biodistribution of these tracers using \[⁶⁸Ga\]Ga-HT547 and \[¹⁷⁷Lu\]Lu-HT547 SPECT/CT.

Eligibility criteria

Qualifiers

Willing and able to communicate with the investigator, understand and comply with trial requirements, voluntarily participate in the trial, and provide written informed consent.

Aged 18 years or older, regardless of gender.

Expected survival of at least 3 months.

Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.

Disqualifiers

Pregnant or breastfeeding women, or women with a positive baseline pregnancy test.

History of severe allergic reaction to any component of the investigational drug injection.

Received blood transfusion within 4 weeks prior to screening to meet the enrollment criteria.

Received immunotherapy, chemotherapy, radiotherapy, or other anti-tumor therapy within 4 weeks prior to the first dose.

Trial design

Treatments tested in this trial

  • [⁶⁸Ga]Ga-HT547 and [¹⁷⁷Lu]Lu-HT547

Treatment groups

20 Participants
are divided into 1 treatment group

Locations

This trial has no locations

Sponsors and collaborators

Hua Pang

Lead sponsor

First Affiliated Hospital of Chongqing Medical University

Sponsor institution

Source ClinicalTrials.gov